Autologous Mesechymal Stem Cells derived from adipose tissue(Clínica Universidad de Navarra)

Primary outcome measure:
Evaluation of viability, security and tolerance of the adipose-derived mesenchymal stem cells implant (ASCs) in fistulizing Crohn's disease patients, collecting the reactions and adverse events occurred during the study.
Secondary outcome measures:
Evaluating the Adipose-derived mesenchymal stem cells therapeutic effect, in particular:
Fistulas healing efficiency
Changes in quality of life in patients treated
Changes of systemic Crohn's disease after implant
Relapse rate monitored among patients who achieved Adipose-derived mesenchymal Stem Cells treatment success.
Achieving the biological characterization of the cell product used and its correlation with the therapeutic effect measured with:
Phenotype study
Suppressor capacity study.
Citoquines production analysis